StockStory.org on MSN
Research tools & consumables stocks Q3 results: Benchmarking Bio-Techne (NASDAQ:TECH)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
"The Bio-Techne team once again executed at a high level and delivered strong second quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "It is encouraging to ...
Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...
Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...
With a recent deal struck to buy B-MoGen Biotechnologies Inc., Minneapolis-based biotechnology manufacturer Bio-Techne has made its 15th acquisition within five years. Bio-Techne will acquire all ...
In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...
MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...
Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results